BBP

Cathie Wood Says ESG Concerns Over Bitcoin Are Temporary

Record Cash Pours Into $4 Billion Fund in Infrastructure Bet

BlackRock’s Fink Raises Salaries 8% While He Eyes Inflation Risk

A $15.3 Billion Quant ETF Loses Out in Badly-Timed Rebalance

Dot-Com Survivor Ryan Jacob Channels Cathie Wood With First ETF

Cathie Wood Sells China Tech Stocks, Warning of Valuation Reset

Mystery Surrounds $7 Billion Outflow From Vanguard S&P 500 Fund

Biotech Investing In A Time Of The Coronavirus

A broad and diverse effort is underway by biotech companies to solve the terrible riddle of the Coronavirus.Firms are forging ahead with testing, treatment and vaccine research and product development.Results of even the most promising treatments, however, are not yet clear cut. Even those that may be are not proof a bullish thesis for those companies that have developed them.Biotech investing is risky. The temptations of building a large position in a COVID 19-engaged public company are obvious.A wise investor would be well-served by opening or adding to such positions with a measure of caution.